[HTML] frontiersin.org

[HTML][HTML] Recent progress and advances in stimuli-responsive polymers for cancer therapy

NV Rao, H Ko, J Lee, JH Park - Frontiers in bioengineering and …, 2018 - frontiersin.org
The conventional chemotherapeutic agents, used for cancer chemotherapy, have major
limitations including non-specificity, ubiquitous biodistribution, low concentration in tumor …
被引用次数：135 相关文章

Recent Progress and Advances in Stimuli-Responsive Polymers for Cancer Therapy

NV Rao, H Ko, J Lee, JH Park - … in bioengineering and …, 2018 - pubmed.ncbi.nlm.nih.gov
The conventional chemotherapeutic agents, used for cancer chemotherapy, have major
limitations including non-specificity, ubiquitous biodistribution, low concentration in tumor …
[HTML] nih.gov

[HTML][HTML] Recent Progress and Advances in Stimuli-Responsive Polymers for Cancer Therapy

NV Rao, H Ko, J Lee, JH Park - Frontiers in Bioengineering and …, 2018 - ncbi.nlm.nih.gov
The conventional chemotherapeutic agents, used for cancer chemotherapy, have major
limitations including non-specificity, ubiquitous biodistribution, low concentration in tumor …

Recent Progress and Advances in Stimuli-Responsive Polymers for Cancer Therapy.

NV Rao, H Ko, J Lee, JH Park - Frontiers in Bioengineering and …, 2018 - europepmc.org
The conventional chemotherapeutic agents, used for cancer chemotherapy, have major
limitations including non-specificity, ubiquitous biodistribution, low concentration in tumor …

Recent progress and advances in stimuli-responsive polymers for cancer therapy

V Rao - Frontiers in Bioengineering and Biotechnology, 2018 - scholarworks.bwise.kr
The conventional chemotherapeutic agents, used for cancer chemotherapy, have major
limitations including non-specificity, ubiquitous biodistribution, low concentration in tumor …
[PDF] archive.org

[PDF][PDF] Recent Progress and Advances in Stimuli-Responsive Polymers for Cancer Therapy

NV Rao, H Ko, J Lee, JH Park - Front. Bioeng. Biotechnol. 6: 110 …, 2018 - scholar.archive.org
The conventional chemotherapeutic agents, used for cancer chemotherapy, have major
limitations including non-specificity, ubiquitous biodistribution, low concentration in tumor …